Results of a Phase I-II Study of Fenretinide and Rituximab for Patients with Indolent B-Cell Lymphoma and Mantle Cell Lymphoma

Fenretinide, a synthetic retinoid, induces apoptotic cell death in B-cell non-Hodgkin lymphoma (B-NHL) and acts synergistically with rituximab in preclinical models. We report results from a phase I–II study of fenretinide with rituximab for B-NHLs. Eligible diagnoses included indolent B-NHL or mant...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Autores principales: Cowan, Andrew J., Stevenson, Phillip A., Gooley, Ted A., Frayo, Shani L., Oliveira, George R., Smith, Stephen D., Green, Damian J., Roden, Jennifer E., Pagel, John M., Wood, Brent L., Press, Oliver W., Gopal, Ajay K.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5303179/
https://ncbi.nlm.nih.gov/pubmed/28055107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14451
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares